T0318

Tranilast

≥98% (HPLC), powder

• 동의어(들): 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid, 3,4-DAA, N-(3,4-Dimethoxycinnamoyl)anthranilic acid, Rizaben, SB-252218
• 실험식(Hill 표기법): C₁₈H₁₇NO₅
• CAS Number: 53902-12-8
• Molecular Weight: 327.33
• MDL number: MFCD00864787
• UNSPSC 코드: 41106500
• PubChem Substance ID: 24278719
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥98% (HPLC)
• 양식: powder
• 색상: white to beige
• mp: 166.2-168.2 °C (lit.)
• solubility: DMSO: >10 mg/mL; H₂O: insoluble
• 주관자: Kissei
• 저장 온도: 2-8°C
• SMILES string: COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC
• InChI: 1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
• InChI key: NZHGWWWHIYHZNX-CSKARUKUSA-N
• 유전자 정보: human ... VEGFA(7422), VEGFB(7423), VEGFC(7424)

설명

애플리케이션

The effect of Tranilast on mast cell surface receptors was studied in murine bone marrow-derived mast cells.

생화학적/생리학적 작용

Tranilast also inhibits vascular smooth muscle cell proliferation by inhibiting the cyclin-dependent kinase inhibitor-1(p21Waf1/Cip1) and may be useful in treating cardiac allograft vasculopathy. It is used in treating hypertrophic scars and keloids. Tranilast inhibits tumor necrosis factor (TNF-α and TGF-β2), obstructing epithelial-mesenchymal transition in human retinal pigment epithelial cell line (ARPE).

Tranilast is an anti-asthma drug, which inhibits LTC₄ and PGE₂ formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing T_H1-mediated autoimmune diseases.

Tranilast is an anti-asthma drug, which inhibits LTC₄ and PGE₂ formation in stimulated monocytes, inhibits mast cell degranulation, and inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro.

특징 및 장점

This compound was developed by Kissei. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

안전성 정보

• 픽토그램: GHS07
• 신호어: Warning
• 유해 및 위험 성명서: H302
• 예방조치 성명서: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• 개인 보호 장비: dust mask type N95 (US), Eyeshields, Gloves